[ad_1]
SUZHOU, China, February 3, 2019 / PRNewswire / – On February 1, 2019, GeneQuantum Healthcare from Suzhou and MITRO Biotech from Nanjing Signed Strategic Cooperation Agreement on the Development of Next Generation Radionuclide Conjugates Nanjing. Dr. Gang Qin, President of GeneQuantum and Dr. Xinping Li, CEO of MITRO, attended the signing ceremony with their teams.
In search of mutual benefits win-win cooperationot Both parties intend to integrate GeneQuantum's leading bioconjugation platform and the unique advantages of MITRO in radiolabeling and molecular imaging techniques to jointly develop conjugates of Next-generation radionuclides for fast and effective companion diagnosis and targeted targeted tumor therapy.
"Since its inception, GeneQuantum has committed to setting up a differentiated innovation platform to address the key challenges of the biopharmaceutical industry. Based on our patented Ligase-Dependent Conjugation (LDC) technology, GeneQuantum has progressively implemented an Intelligent Automatic Convergence System (iLDC) with a fully integrated simultaneous manufacturing process; combined with our comprehensive quality system that meets global standards, GeneQuantum can provide a comprehensive solution for the efficient development and manufacture of all types of site-specific bioconjugates. MITRO, on the other hand, has a unique technology platform for the production and labeling of radionuclides," said Dr. Gang Qin. "We are pleased to work with a leading and distinctive technology partner, such as MITRO, to develop next-generation radionuclide conjugates for diagnostic and therapeutic purposes, meeting the unmet clinical needs of cancer patients worldwide."
"MITRO focuses on the development and application of molecular imaging and isotopic labeling technology and is committed to establishing a biomedical research platform on innovation and transformation, using advanced labeling technology isotope and molecular imaging to develop new drugs," says the doctor Xinping Li. "We are happy to work with GeneQuantum Healthcare on the basis of our mutual interest in advanced medicine. This cooperation will fully integrate GeneQuantum's technical and resource advantages in site-specific bioconjugation and MITRO in isotope labeling and non-invasive molecular imaging technology. The collaboration will create an internationally competitive platform for bioconjugates of radionuclides for medical use. This will contribute to the most effective noninvasive diagnosis of cancer and precise targeted therapy, as well as a systemic solution for the development of new biomedical drugs."
About GeneQuantum Healthcare
Founded in the Suzhou Industrial Park in 2013, GeneQuantum Healthcare (Suzhou) Co., Ltd. is a biotechnology company specializing in the development of innovative biological therapeutics and diagnostics. The company has an innovative and leading independent platform for bioconjugation of drug development and manufacturing, and is engaged in the development of a series of anti-tumor antibody-drug-conjugate (ADC) conjugates to meet the unsatisfied clinical demands worldwide.
About MITRO Biotech
MITRO is the first CRO in molecular imaging of China and a national high-tech company. The company was founded in Wuxi in 2010 and settled in the Nanjing Jiangning High-tech Industrial Development Zone in 2012. The company uses isotope labeling and molecular imaging technology in vivo to provide clients with comprehensive solutions and outsourced technical services for the development of new drugs, including drug screening, biodistribution, pharmacokinetics and pharmacodynamics. MITRO provides the translational research service of bad mice, rats, monkeys to humans. The technology has exceptional advantages: in vivo imaging. Quantitative dynamic quantitative badysis, self-control, and continuous observation can dramatically shorten the drug's development cycle, reduce research and development costs, and reduce the risk of failure. www.mi-tro.com/en/
See the original content: https: //www.prnewswire.com/news-releases/genequantum-healthcare-and-mitro-biotech-enter-into-stro-strategic-cooperation-to-develop-next-generation-radionuclide-conjugates -300 788 721. html
SOURCE GeneQuantum
[ad_2]
Source link
